Dec. 22, 2022--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will be participating in the 41st Annual J.P. Morgan Healthcare Conference taking place at the Westin St. Francis, San Francisco, CA on January 9-12, 2023.
Quantum-Si’s management will present on Thursday, January 12 at 10:30 am Pacific Standard Time. The discussions will cover recent company developments, including the recently-announced commercial availability of Quantum-Si’s groundbreaking Platinum™ instrument, which is the first system to enable next-generation, single-molecule protein sequencing.
A live and archived webcast of the events will be available in the Investors section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.
| Last Trade: | US$2.00 |
| Daily Change: | -0.15 -6.98 |
| Daily Volume: | 1,836,757 |
| Market Cap: | US$365.120M |
September 23, 2025 September 08, 2025 August 05, 2025 June 17, 2025 | |

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load